PALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that data from the Phase 3 pivotal studies of investigational drug Crisaborole Topical Ointment, 2% will be presented at two upcoming medical meetings.
The Fall Clinical Dermatology Conference, October 1-4, 2015 in Las Vegas, Nevada
The following abstracts have recently been accepted for poster
- “Results from Two Phase 3 Studies in Children and Adults with Mild to Moderate Atopic Dermatitis Treated with Crisaborole Topical Ointment, 2%, a Novel Nonsteroidal, Topical Anti-Inflammatory, Phosphodiesterase 4 Inhibitor”
- “Evaluation of Pruritus and Signs of Atopic Dermatitis With Crisaborole Topical Ointment, 2%, a Novel Nonsteroidal, Topical Anti-Inflammatory, Phosphodiesterase 4 Inhibitor in Two Phase 3 Studies in Children and Adults With Mild to Moderate Atopic Dermatitis”
The 24th European Academy of Dermatology and Venereology Congress, October 7-11, 2015 in Copenhagen, Denmark
- LATCOP-0093, “Treatment of children and adults with mild to moderate atopic dermatitis with Crisaborole Topical Ointment, 2%, a novel, nonsteroidal, topical anti-inflammatory, phosphodiesterase 4 inhibitor: results from two phase 3 studies” will be presented during the late breaking news session on Saturday, October 10, between 8:00 a.m. and 11:15 a.m. CEST by Mark Lebwohl, M.D., Sol and Clara Kest Professor and Chair of the Department of Dermatology at the Icahn School of Medicine at Mount Sinai.
About Anacor Pharmaceuticals
Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor’s first approved drug, KERYDIN® (tavaborole) topical solution, 5%, is an oxaborole antifungal approved by the U.S. Food and Drug Administration in July 2014 for the topical treatment of onychomycosis of the toenails. In July 2014, Anacor entered into an exclusive agreement with Sandoz Inc., a Novartis company, pursuant to which PharmaDerm, the branded dermatology division of Sandoz, distributes and commercializes KERYDIN in the United States. In September 2014, PharmaDerm launched KERYDIN in the United States. Anacor’s lead product development candidate is crisaborole topical ointment, 2%, a novel non-steroidal topical anti-inflammatory PDE-4 inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis and psoriasis. Beyond KERYDIN and crisaborole, Anacor has discovered three investigational compounds that it has out-licensed for further development. The first compound is licensed to Eli Lilly and Company for the potential treatment of an animal health indication. The second compound, AN5568, also referred to as SCYX-7158, is licensed to Drugs for Neglected Diseases initiative for the potential treatment of human African trypanosomiasis. The third compound is licensed to GlaxoSmithKline LLC for development in tuberculosis. Anacor also has a pipeline of other internally discovered topical and systemic boron-based compounds in early stages of research and development. These include AN3365, an investigational Gram-negative antibiotic, and certain other wholly-owned investigational product candidates. For more information, visit www.anacor.com.